A New Drug Application was submitted to the FDA for a novel, nonhormonal dual neurokinin-1 and neurokinin-3 receptor antagonist for the treatment of menopause-related vasomotor symptoms.
This review and meta-analysis reviews the effectiveness of cognitive behavioral therapy and mindfulness interventions for depression, anxiety, and cognitive functioning in women undergoing menopausal transition. Â
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
CBT is effective for the management of vasomotor symptoms, depression, and sleep in perimenopausal women.
Recent studies suggest that the burden of menopausal symptoms is greater than generally perceived. About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the [...]
For decades, estrogen was used as a component of hormone replacement therapy to treat menopausal symptoms, including hot flashes, night sweats, and sleep disturbance; however, after several large, prospective studies (e.g., HERS, WHI) questioned the [...]
Peri- and post-menopausal women frequently complain of insomnia or poor sleep quality. Sleep disturbance is often attributed to nocturnal hot flashes; however, a sizeable proportion of menopausal women may have a primary sleep disorder. Â Â Â As [...]
Many women report cognitive difficulties — forgetfulness, distractibility, feeling foggy — as they enter into the menopause. Looking at sex-related differences in memory, Rentz and colleagues examined 212 men and women between the ages of [...]
Several recent articles suggest that the burden of menopausal symptoms is greater than generally perceived. About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats -- as they transition into the [...]
The US Food and Drug Administration (FDA) has approved a novel estrogen-based drug for women for the treatment of moderate-to-severe vasomotor symptoms and osteoporosis associated with menopause. Duavee (Wyeth Pharmaceuticals) is a once-a-day tablet containing a combination of conjugated estrogens and bazedoxifene, an estrogen agonist/antagonist.
